BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma

Leukemia

Volumn 29, Issue 6, 2015, Pages 1402-1413

  Esmailzadeh, S ^a,b   Huang, Y ^a,b,c   Su, M W ^b,c   Zhou, Y ^b,c   Jiang, X ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRIDGING INTEGRATOR 1 PROTEIN; CASPASE 3; CASPASE 8; CD4 ANTIGEN; CD7 ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; UNCLASSIFIED DRUG; BIN1 PROTEIN, HUMAN; CFLAR PROTEIN, HUMAN; FAS ANTIGEN; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLONY FORMING CELL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MYCOSIS FUNGOIDES; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY CELL; SEZARY SYNDROME; SKIN BIOPSY; THYMIDINE INCORPORATION ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; CASE CONTROL STUDY; CELL CYCLE; COMPARATIVE STUDY; CUTANEOUS T CELL LYMPHOMA; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; SKIN TUMOR; TUMOR CELL CULTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE; CELL PROLIFERATION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84930575283     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.9     Document Type: Article

References (59)

1. Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012; 4: 75-89.
2. Klemke CD, Goerdt S, Schrama D, Becker JC. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 2006; 4: 395-406.
3. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371: 945-957.
4. Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008; 22: 393-399.
5. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477-1488.
6. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
7. Dulmage BO, Geskin LJ. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol 2013; 169: 1188-1197.
8. Wang Y, Su M, Zhou LL, Tu P, Zhang X, Jiang X et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011; 117: 3826-3835.
9. Mao X, Orchard G, Mitchell TJ, Oyama N, Russell-Jones R, Vermeer MH et al. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 2008; 35: 899-910.
10. Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs 2014; 23: 457-467.
11. van Doorn R, van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113: 127-136.
12. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118: 5891-5900.
13. Contassot E, Kerl K, Roques S, Shane R, Gaide O, Dupuis M et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 2008; 111: 4780-4787.
14. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 2007; 127: 2425-2437.
15. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129: 1165-1173.
16. Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2011; 508: 185-191.
17. Valente G, Manfroi F, Peracchio C, Nicotra G, Castino R, Nicosia G et al. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol 2006; 132: 560-570.
18. Dummer R, Michie SA, Kell D, Gould JW, Haeffner AC, Smoller BR et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995; 22: 11-17.
19. van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002; 62: 5389-5392.
20. Ringrose A, Zhou Y, Pang E, Zhou L, Lin AE, Sheng G et al. Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas. Leukemia 2006; 20: 1593-1601.
21. Kennah E, Ringrose A, Zhou LL, Esmailzadeh S, Qian H, Su MW et al. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood 2009; 113: 4646-4655.
22. Esmailzadeh S, Jiang X. AHI-1: A novel signaling protein and potential therapeutic target in human leukemia and brain disorders. Oncotarget 2011; 2: 918-934.
23. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYCinteracting protein with features of a tumour suppressor. Nat Genet 1996; 14: 69-77.
24. Wechsler-Reya RJ, Elliott KJ, Prendergast GC. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol 1998; 18: 566-575.
25. Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 2000; 19: 4669-4684.
26. DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 2003; 88: 635-642.
27. Cassimere EK, Pyndiah S, Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ 2009; 16: 1641-1653.
28. Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. J Cell Physiol 2008; 216: 621-631.
29. Prokic I, Cowling BS, Laporte J. Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (Berl) 2014; 124: 976-978.
30. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 2000; 85: 376-383.
31. Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 2003; 9: 3345-3355.
32. Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 2007; 67: 7605-7612.
33. Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta 2009; 1795: 25-36.
34. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 1999; 96: 9689-9694.
35. Ghaneie A, Zemba-Palko V, Itoh H, Itoh K, Sakamuro D, Nakamura S et al. Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther 2007; 6: 192-194.
36. Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000; 86: 155-161.
37. Galderisi U, Di Bernardo G, Cipollaro M, Jori FP, Piegari E, Cascino A et al. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein. J Cell Biochem 1999; 74: 313-322.
38. Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 1999; 18: 3564-3573.
39. Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R et al. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 2005; 351: 182-194.
40. Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE et al. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med 2008; 205: 2657-2671.
41. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
42. Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 2013; 105: 405-423.
43. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680-693.
44. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31: 229-234.
45. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
46. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
47. Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem 1997; 272: 31453-31458.
48. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996; 88: 2385-2409.
49. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2908-2925.
50. Kuzel TM. Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome. Dermatol Ther 2003; 16: 355-361.
51. Valnet-Rabier MB, Challier B, Thiebault S, Angonin R, Margueritte G, Mougin C et al. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 2005; 128: 767-773.
52. El-Gazzar A, Wittinger M, Perco P, Anees M, Horvat R, Mikulits W et al. The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecol Oncol 2010; 117: 451-459.
53. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008; 76: 1694-1704.
54. Haag C, Stadel D, Zhou S, Bachem MG, Moller P, Debatin KM et al. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011; 60: 225-237.
55. Yang BF, Xiao C, Li H, Yang SJ. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation. Clin Exp Pharmacol Physiol 2007; 34: 1245-1251.
56. Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG et al. In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis 2010; 15: 1435-1443.
57. Day TW, Najafi F, Wu CH, Safa AR. Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for Taxol-induced apoptosis. Biochem Pharmacol 2006; 71: 1551-1561.
58. Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 2011; 3: 1639-1671.
59. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr Cancer Drug Targets 2008; 8: 37-46.